Provided by Tiger Trade Technology Pte. Ltd.

AC Immune SA

2.62
-0.2900-9.97%
Pre-market: 2.59-0.0264-1.01%08:00 EST
Volume:779.08K
Turnover:2.03M
Market Cap:264.62M
PE:-2.90
High:2.75
Open:2.63
Low:2.45
Close:2.91
52wk High:4.00
52wk Low:1.43
Shares:101.00M
Float Shares:40.95M
Volume Ratio:3.88
T/O Rate:1.90%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9039
EPS(LYR):-0.5636
ROE:-74.63%
ROA:-21.97%
PB:3.29
PE(LYR):-4.65

Loading ...

AC Immune Says Recruitment Temporarily Paused in Ongoing Study for Alzheimer's Disease Treatment

MT Newswires Live
·
18 hours ago

BRIEF-Ac Immune Says Informed Enrollment Has Been Temporarily Paused For Phase 2B Retain Trial

Reuters
·
Yesterday

AC Immune Sa: Informed by Janssen Pharmaceuticals That Enrollment Has Been Temporarily Paused for Phase 2B Retain Trial

THOMSON REUTERS
·
Yesterday

AC Immune Sa: Temporary Pause in Phase 2B Retain Trial Recruitment Is Voluntary & Not Related to New Safety Findings

THOMSON REUTERS
·
Yesterday

Startup Lifordi Seeks to Deliver Potent Medication for Autoimmune Diseases -- WSJ

Dow Jones
·
Dec 26, 2025

Discovering Opportunities: AirJoule Technologies Among 3 Promising Penny Stocks

Simply Wall St.
·
Dec 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Roku, Ciena, Diamond Hill

Reuters
·
Dec 11, 2025

AC Immune Shares Climb 32.6% Premarket After Co Reports Positive Trial Data for Parkinson's Disease Therapy

THOMSON REUTERS
·
Dec 11, 2025

AC Immune Sa - ACI-7104.056 Shows Clear Safety Profile

THOMSON REUTERS
·
Dec 11, 2025

AC Immune Sa - Targets Met for Immunogenicity and Pharmacodynamics

THOMSON REUTERS
·
Dec 11, 2025

AC Immune Sa - Immunotherapy Could Slow Parkinson's Progression

THOMSON REUTERS
·
Dec 11, 2025

AC Immune Positive Interim Phase 2 Data on ACI-7104.056 Support Potential Slowing of Progression of Parkinson’s Disease

GlobeNewswire
·
Dec 11, 2025

AC Immune SA to Present at Jefferies London Healthcare Conference

Reuters
·
Nov 11, 2025

AC Immune Price Target Maintained With a $8.00/Share by BTIG

Dow Jones
·
Nov 05, 2025

AC Immune SA reports results for the quarter ended September 30 - Earnings Summary

Reuters
·
Nov 04, 2025

AC Immune SA Reports Decline in Q3 2025 Financial Results

TIPRANKS
·
Nov 04, 2025

AC Immune Q3 EPS $(0.20) Beats $(0.22) Estimate, Sales $1.174M Miss $1.520M Estimate

Benzinga
·
Nov 04, 2025

BRIEF-AC Immune Q3 Operating Income CHF -16.166 Million

Reuters
·
Nov 04, 2025

AC Immune SA reports third quarter results and updates pipeline focus

Reuters
·
Nov 04, 2025

AC Immune Q3 Operating Expenses CHF -17.105 Million

THOMSON REUTERS
·
Nov 04, 2025